Denosumab beta-cell preservation
Academic / repurposed Prolia/Xgeva mechanism
A repurposing hypothesis around denosumab, the RANKL-targeting osteoporosis drug, to protect or improve beta-cell function in early T1D. A phase 1/2 trial is recruiting, but human T1D efficacy is unproven.
The scorecard
The registry and funder rationale cite lab evidence that the RANKL pathway may affect beta-cell health, but no T1D efficacy result is posted.[1]
Durability is unknown; the current trial tests intermittent dosing over time rather than a proven lasting beta-cell rescue.[2]
Denosumab is approved for other diseases, but its risk-benefit in young or early T1D populations is unproven and requires trial monitoring.[1]
The study targets early T1D, roughly 1-5 years from diagnosis, not long-established disease broadly.[1]
The full picture
Denosumab is not a diabetes drug today. The reason it belongs on the horizon list is mechanism: RANKL signaling may influence beta-cell health, and denosumab already has a known clinical pharmacology in other indications. The trial will decide whether that biology translates into safer glucose control or preserved beta-cell function in people with early T1D.
Coming soon
ETA · Phase 1/2 recruiting; primary completion estimated 2027
Sources